Supplementary Figure S4 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma
Year: 2026
Type: supplementary-materials
Abstract: Signaling consequences in Fadu parental, AfaR, or ErlR cells of treatment with VIC-1911 alone or in combination with erlotinib or afatinib
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7202356878
Cites:
Cited by:
Related to: